Nuformix (LON:NFX) Stock Price Up 17.6% – Should You Buy?

Shares of Nuformix plc (LON:NFXGet Free Report) rose 17.6% during trading on Friday . The stock traded as high as GBX 0.31 and last traded at GBX 0.30. Approximately 22,581,281 shares traded hands during trading, a decline of 57% from the average daily volume of 53,071,184 shares. The stock had previously closed at GBX 0.26.

Nuformix Stock Up 5.9%

The firm has a 50-day moving average of GBX 0.29 and a two-hundred day moving average of GBX 0.19. The company has a market capitalization of £5.70 million, a PE ratio of -0.69 and a beta of 1.22.

Nuformix Company Profile

(Get Free Report)

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.

Featured Stories

Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.